RxDoctor Payments Data

Pennye Rohde

Physician Assistant · Houston, TXNPI 1184779456

Payments from drug & device makers

$22,790in general payments, 2019–2025

Across 143 payments — averaging $159.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$20K
  • Janssen Products, LP$1K
  • Theratechnologies Inc.$424
  • Johnson & Johnson$274
  • Viiv Healthcare Company$167
  • Merck$144
  • plus $256 from 3 others

What the payments were for

  • Consulting fees$1,9909%
  • Speaking & faculty fees$13,32358%
  • Travel & lodging$3,30114%
  • Food & beverage$4,07618%
  • Education$1000%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,790 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$12,620
Medicare patients
22
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala40$156,962
OzempicSemaglutide94$119,189
JardianceEmpagliflozin91$92,790
MounjaroTirzepatide43$45,923
EliquisApixaban43$38,217
TradjentaLinagliptin28$27,365
Atrovent HfaIpratropium Bromide57$27,356
EntrestoSacubitril/Valsartan16$16,294
JanuviaSitagliptin Phosphate13$12,767
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,891
SymbicortBudesonide/Formoterol Fumarate37$10,600
Spiriva RespimatTiotropium Bromide16$9,701
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$6,577
Breo ElliptaFluticasone/Vilanterol12$4,900
Albuterol Sulfate HfaAlbuterol Sulfate133$3,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$20,302$156,96240 claims
MerckJanuvia$144$12,76713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →